{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
ICU Medical, Inc.
ICU Medical Experiences Revision in Stock Evaluation Amid Market Volatility
ICU Medical, Inc. has experienced notable stock fluctuations, with a current price of $123.48 and a 52-week range between $107.00 and $196.26. The company's performance has lagged behind the S&P 500, showing significant declines over the past year and longer periods, indicating ongoing challenges in the market.
ICU Medical, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
ICU Medical, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has faced significant challenges over the past year, with a notable decline in stock performance compared to the S&P 500. Current trading reflects mixed technical indicators, suggesting a need for strategic adjustments amid fluctuating market conditions.
Is ICU Medical, Inc. technically bullish or bearish?
As of October 3, 2025, ICU Medical, Inc. shows a mildly bearish technical trend, with mixed signals from MACD and KST, and has underperformed the S&P 500 significantly year-to-date and over the past year.
Is ICU Medical, Inc. technically bullish or bearish?
As of October 3, 2025, ICU Medical, Inc. exhibits a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 with a year-to-date return of -21.33% compared to the S&P's 14.18%.
Is ICU Medical, Inc. technically bullish or bearish?
As of September 4, 2025, ICU Medical, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and underperformance against the S&P 500, with year-to-date and one-year returns of -14.27% and -24.51%, respectively.
Is ICU Medical, Inc. overvalued or undervalued?
As of November 7, 2022, ICU Medical, Inc. is considered overvalued and risky due to its high EV to EBITDA ratio of 13.71, low ROCE of 3.62%, and poor stock performance compared to peers and the S&P 500.
Is ICU Medical, Inc. technically bullish or bearish?
As of May 10, 2024, ICU Medical, Inc. exhibits a mildly bearish trend, supported by bearish MACD and moving averages, along with mixed signals from the KST and Bollinger Bands.
Is ICU Medical, Inc. overvalued or undervalued?
As of November 7, 2022, ICU Medical, Inc. is considered overvalued and risky, with poor financial metrics such as a negative P/E ratio of -82.12 and a year-to-date return of -17.46%, indicating it is not generating adequate returns compared to its peers and the S&P 500.
Who are in the management team of ICU Medical, Inc.?
As of March 2022, the management team of ICU Medical, Inc. includes Chairman and CEO Vivek Jain, Lead Independent Director David Greenberg, Directors George Lopez, Donald Abbey, Elisha Finney, and David Hoffmeister. They are responsible for the company's strategic direction and governance.
What does ICU Medical, Inc. do?
ICU Medical, Inc. develops and sells medical devices for infusion therapy, oncology, and critical care, with recent net sales of $604 million and a market cap of approximately $3.2 billion. The company reported a net profit of -$15 million for the most recent quarter.
How big is ICU Medical, Inc.?
As of Jun 18, ICU Medical, Inc. has a market capitalization of 3,198.84 million, with net sales of 2,417.10 million and a net profit of -93.70 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
